Vnitr Lek 2017, 63(10):717-720 | DOI: 10.36290/vnl.2017.142

Diabetes mellitus and cognitive disorders from the diabetologist's perspective

Alena ©mahelová
III. interní gerontometabolická klinika LF UK a FN Hradec Králové

Diabetes mellitus is associated with cognitive impairment which may convert to vascular or neurodegenerative dementia. Impairment of cognitive functions affects patients with type 1 and especially type 2 diabetes, with a number of vascular, metabolic and psychosocial factors involved in its development. As hyperglycemia and hypoglycemia also play an important role, important is the correct strategy of diabetes therapy which utilizes a combination of metformin with modern safe antidiabetics (incretin drugs, gliflozins, insulin analogues). It seems that some antidiabetic drugs (metformin, incretin drugs) and nasal form of application of insulin could improve cognition in diabetics.

Keywords: antidiabetic drugs; diabetes mellitus; hyperglycemia; hypoglycemia; cognition

Received: September 9, 2017; Accepted: September 27, 2017; Published: October 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©mahelová A. Diabetes mellitus and cognitive disorders from the diabetologist's perspective. Vnitr Lek. 2017;63(10):717-720. doi: 10.36290/vnl.2017.142.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Feinkohl I, Price JF, Strachan M et al. The impact of diabetes on cognitive decline: potential vascular, metabolic, and psychosocial risk factors. Alzheimers Res Ther 2015; 7(1): 46. Dostupné z DOI: <http://dx.doi.org/10.1186/s13195-015-0130-5>. Go to original source... Go to PubMed...
    2. Seaquist E. The Final Frontier: How Does Diabetes Affect the Brain? Diabetes 2010; 59(1): 4-5. Dostupné z DOI: <http://dx.doi.org/10.2337/db09-1600>. Go to original source... Go to PubMed...
    3. Kawamura T, Umamura T, Hotta N. Cognitive impairment in diabetic patients: Can diabetic control prevent cognitive decline? J Diabetes Investig 2012; 3(5): 413-423. Dostupné z DOI: <http://dx.doi.org/10.1111/j.2040-1124.2012.00234.x>. Go to original source... Go to PubMed...
    4. Cukierman-Yaffe T, Gerstein HC, Williamson JD et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 2009; 32(2): 221-226. Dostupné z DOI: <http://dx.doi.org/10.2337/dc08-1153>. Go to original source... Go to PubMed...
    5. Viberti G, Kahn SE, Greene DA et al. A Diabetes Outcome Progression Trial (ADOPT). An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25(10): 1737-1743. Go to original source... Go to PubMed...
    6. Patel A, MacMahon S, Chalmers J et al. [The ADVANCE Collaborative Group]. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008; 358(24): 2560-2572. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0802987>. Go to original source... Go to PubMed...
    7. Whitmer RA, Karter AJ, Yaffe KF et al. Hypoglycemic Episodes and Risk of Dementia in Older Patients With Type 2 Diabetes Mellitus. JAMA 2009; 301(15): 1565-1572. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2009.460>. Go to original source... Go to PubMed...
    8. De Pablos-Velasco P, Bradley C, de Pablos-Velasco E et al. The PANORAMA an-European Survey: impact of severe and non-severe hypoglycaemia on quality of life and other patient reported outcomnes in patient with type 2 diabetes (Abstract 580). Diabetologia 2010; 53(Suppl 1): S234-S236.
    9. Inzucchi S, Bergenstal R, Buse J. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38(1): 140-149. Dostupné z DOI: <https://doi.org/10.2337/dc14-2441>. Go to original source... Go to PubMed...
    10. Alagiakrishnan K, Sankaralingam S, Ghosh M et al. Antidiabetic Drugs and Their Potential Role in Treating Mild Cognitive Impairment and Alzheimer's Disease. Discov Med 2013; 16(90): 277-286. Go to PubMed...
    11. Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012; 13: 33. Dostupné z DOI: <http://dx.doi.org/10.1186/1471-2202-13-33>. Go to original source... Go to PubMed...
    12. Yang Y, Zhang J, Ma D et al. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J Alzheimers Dis 2013; 37(3): 637-648. Dostupné z DOI: <http://dx.doi.org/10.3233/JAD-130491>. Go to original source... Go to PubMed...
    13. Salcedo I, Tweedie D, Li Y et al. Neurtoprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegerative and cerebrovascular disorders. Br J Pharmacol. 2012; 166(5): 1586-1599. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1476-5381.2012.01971.x>. Go to original source... Go to PubMed...
    14. Duarte AI, Candeias E, Correia G et al. Crosstalk between diabetes and brain: Glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochim Biophys Acta 2013; 1832(4): 527-541. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bbadis.2013.01.008>. Go to original source... Go to PubMed...
    15. Craft S, Baker LD, Montine TJ et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012; 69(1): 29-38. Dostupné z DOI: <http://dx.doi.org/10.1001/archneurol.2011.233>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.